Pombiliti Atga is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Pombiliti Atga is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand namePombiliti Atga
Authorized genericcipaglucosidase alfa-atga
Regular genericcipaglucosidase alfa-atga
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Pombiliti Atga?
The original
–
–

Brand nameThe maker’s card

AMICUS ASSIST Co-Pay Assistance

Savings card from Amicus Therapeutics

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on pombilitiopfoldahcp.com 

Or call 1-833-264-2872.

In the maker’s words

“Eligible commercially or privately insured patients may pay as little as $0 per month for treatment…”

From the maker’s offer on pombilitiopfoldahcp.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Pombiliti Atga itself, from the same company, sold without the brand name, and usually for less. For now Pombiliti Atga is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Pombiliti Atga is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

POMBILITI is a hydrolytic lysosomal glycogen-specific enzyme indicated, in combination with Opfolda, an enzyme stabilizer, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

Source: the FDA label for Pombiliti Atga (AMICUS THERAPEUTICS US, LLC), August 12, 2026. Full label on DailyMed 

Good to know